MEDIA COVERAGE

Kura’s Leukemia Treatment Performs Best When Tacked Onto Existing Combo, New Data Show

By Max Bayer | Fierce Biotech

In February 2024, Kura announced preliminary data from the Phase 1 trial of ziftomenib in the KOMET-007 clinical trial evaluating it as a combination agent with standards of care including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza).

The data demonstrated encouraging preliminary results for patients with NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML).

Read Fierce Biotech’s full coverage and view the press release with the full data below:

View Coverage View Press Release Back to News & Media